Vor Bio, a clinical-stage biotechnology company, reported first quarter 2026 financial results and announced its cash position of $491.5 million is expected to fund operations into early 2029. The company is advancing two Phase 3 trials of telitacicept, a dual BAFF/APRIL inhibitor. The UPSTREAM MG trial in generalised myasthenia gravis is on track with topline results anticipated in the first half of 2027, whilst enrollment continues for the UPSTREAM SjD trial in primary Sjögren's disease. Research and development expenses decreased to $17.6 million from $26.7 million year-over-year, primarily due to reduced spending on previous programmes. The company reported a net loss of $219.6 million for the quarter, compared to $32.5 million in the same period last year, mainly due to changes in fair value of outstanding liability-classified warrants.

Vor Bio (VOR) said on Friday it had entered a securities purchase agreement to sell 5.34M shares at $14.05 each in a private placement, for gross proceeds of about $75M. The private placement is expected to close on or about March 30, 2026. The financing is led by new investor TCGX. The net proceeds from the offering will be used for advancing teli...

Vor Bio appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors. Rhea-AI summary. Vor Biopharma (Nasdaq: VOR) announced the appointment of Andrew Levin, M.D., Ph.D. of RA Capital and Wouter Joustra of Forbion to its Board of Directors on December 23, 2025. The appointments follow a $150M PIPE financing that included participation from both investors. Vor Bio said the new directors will support advancement of telitacicept through global Phase 3 programs and contribute to financing and governance strategy. Dr. Levin replaces Sarah Reed, who resigned from the Board. Both appointees are described as having deep life-sciences investment and late-stage biotech experience. * $150M PIPE financing completed with participation from RA Capital and Forbion * Board additions bring late-stage clinical and life-science investment expertise * Board support explicitly tied to advancing telitacicept global Phase 3 programs * Board turnover: Sarah Reed resigned and her seat is filled by Dr. Levin On the day this news was published, VOR declined 1.31%, reflecting a mild negative market reaction. Argus tracked a peak move of +17.4% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $591M at that time. Data tracked by StockTitan Argus on the day of publication. BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) - Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced $150M PIPE financing, which included participation from both investors. "Andrew and Wouter bring highly complementary experience in life sciences investment, financing strategy, and board-level oversight. We are delighted to welcome them to our Board at an important moment for the Company," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. "Their perspectives will be invaluable as we advance our global Phase 3 programs and position the Company to drive long-term shareholder value." Dr. Levin is a Partner on the investment team at RA Capital Management, L.P., where he brings deep expertise in life sciences investing and strategic oversight to support innovative biopharma companies across all stages of development. He holds a B.S. in mechanical engineering from Princeton University, and M.D. from Harvard Medical School, and a Ph.D. in biomedical engineering from Massachusetts Institute of Technology. Dr. Levin fills the seat previously held by Sarah Reed, General Counsel at RA Capital, who resigned from the Board. "Vor Bio is at an important inflection point, and I am excited to support the Company as it advances telitacicept through global Phase 3 development and continues to focus on disciplined capital allocation and long-term growth," said Dr. Levin. Mr. Joustra is a General Partner at Forbion, where he is responsible for general fund management, late stage private, cross-over and public investments. Mr. Joustra has served on the boards of several high-growth biotech companies through successful acquisitions and currently serves on the boards of multiple public and private life sciences companies. He holds an M.Sc. in Business Administration and a B.Sc. in International Business and Management from the University of Groningen. "Vor Bio has established an exceptionally strong foundation with telitacicept, and I look forward to contributing my experience in late-stage biotech growth and value creation as the Company scales its clinical programs," said Mr. Joustra. Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "aim," "anticipate," "can," "continue," "could," "design," "enable," "expect," "initiate," "intend," "may," "on-track," "ongoing," "plan," "potential," "should," "target," "update," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio's statements regarding Vor Bio's development plans for telitacicept; and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Who were appointed to the Vor Biopharma board on December 23, 2025 (VOR)? Vor Biopharma appointed Andrew Levin, M.D., Ph.D. (RA Capital) and Wouter Joustra (Forbion) to its board. What capital raise is connected to Vor Biopharma's board appointments (VOR)? The appointments follow a $150M PIPE financing that included participation from RA Capital and Forbion. How will the new VOR board members affect telitacicept development? Company says the new directors will support advancing telitacicept through global Phase 3 programs and provide financing and governance guidance. Which board seat did Andrew Levin fill at Vor Biopharma (VOR)? Dr. Levin filled the board seat previously held by Sarah Reed, who resigned. What backgrounds do the new Vor Biopharma directors have (VOR)? Dr. Levin is a life-sciences investor with M.D./Ph.D. credentials; Mr. Joustra has experience in late-stage biotech investments and value creation.